Press release
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
2023 revenues are expected to be approximately $20 million above top end of guidance AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global
About this update from Natera, Inc.
[{"type":"text","content":"\n2023 revenues are expected to be approximately $20 million above top end of guidance\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following:\n\n\n\nTotal revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022.\n\n\n\nTotal revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compared to $820 million in 2022.\n\n\n\nThese results are also included in a presentation that has been posted to the investor relations section of the Natera website at investor.natera.com. The presentation is being delivered today, at the 42nd Annual J.P. Morgan Healthcare Conference.\n\n\nNatera plans to release its complete fourth quarter and full year 2023 financial results during its earnings call in February 2024.\n\n\nAbout Natera\n\n\nNatera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.\n\n\nForward-Looking Statements\n\n\nThis release contains forward-looking statements, including our preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2023. The preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2023 have not been audited by our independent registered public accounting firm and are based on management’s initial review of our operations and results for the completed fiscal year. These preliminary operational and financial results are subject to revision based upon our year-end closing procedures, final adjustments and the audit to be conduct...